Literature DB >> 17259800

Immunotherapy for Graves' orbitopathy: easy enthusiasm, but let's keep trying.

L Bartalena1, M L Tanda.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17259800     DOI： 10.1007/BF03349216

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


× No keyword cloud information.
  33 in total

Review 1.  New understanding of the role of cytokines in the pathogenesis of Graves' ophthalmopathy.

Authors:  R A Ajjan; A P Weetman
Journal:  J Endocrinol Invest       Date:  2004-03       Impact factor: 4.256

2.  Are there more than antibodies to the thyroid-stimulating hormone receptor that meet the eye in Graves' disease?

Authors:  H A Drexhage
Journal:  Endocrinology       Date:  2006-01       Impact factor: 4.736

Review 3.  Monoclonal antibody therapy.

Authors:  Deirdre O'Mahony; Michael R Bishop
Journal:  Front Biosci       Date:  2006-05-01

Review 4.  Management of Graves' ophthalmopathy: reality and perspectives.

Authors:  L Bartalena; A Pinchera; C Marcocci
Journal:  Endocr Rev       Date:  2000-04       Impact factor: 19.871

Review 5.  Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.

Authors:  Tim Bongartz; Alex J Sutton; Michael J Sweeting; Iain Buchan; Eric L Matteson; Victor Montori
Journal:  JAMA       Date:  2006-05-17       Impact factor: 56.272

Review 6.  Graves' ophthalmopathy: a rational approach to treatment.

Authors:  Wilmar M Wiersinga; Mark F Prummel
Journal:  Trends Endocrinol Metab       Date:  2002-09       Impact factor: 12.015

7.  Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial.

Authors:  Norihiro Nishimoto; Kazuyuki Yoshizaki; Nobuyuki Miyasaka; Kazuhiko Yamamoto; Shinichi Kawai; Tsutomu Takeuchi; Jun Hashimoto; Junichi Azuma; Tadamitsu Kishimoto
Journal:  Arthritis Rheum       Date:  2004-06

8.  Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression.

Authors:  Mario Salvi; Guia Vannucchi; Irene Campi; Stefania Rossi; Paola Bonara; Francesco Sbrozzi; Claudio Guastella; Sabrina Avignone; Giacinta Pirola; Roberto Ratiglia; Paolo Beck-Peccoz
Journal:  Eur J Endocrinol       Date:  2006-04       Impact factor: 6.664

9.  Peroxisome proliferator-activated receptor-gamma gene expression in orbital adipose/connective tissues is increased during the active stage of Graves' ophthalmopathy.

Authors:  Lídia Y Mimura; Sandra M F Villares; Mário L R Monteiro; Isabel C Guazzelli; Walter Bloise
Journal:  Thyroid       Date:  2003-09       Impact factor: 6.568

Review 10.  Effects of Graves' ophthalmopathy on quality of life.

Authors:  W M Wiersinga; M F Prummel; C B Terwee
Journal:  J Endocrinol Invest       Date:  2004-03       Impact factor: 4.256
View more
  2 in total

1.  Thyroid-stimulating immunoglobulins indicate the onset of dysthyroid optic neuropathy.

Authors:  K A Ponto; T Diana; H Binder; N Matheis; S Pitz; N Pfeiffer; G J Kahaly
Journal:  J Endocrinol Invest       Date:  2015-03-04       Impact factor: 4.256

2.  Blood-aqueous barrier integrity in patients with Graves' ophthalmopathy (GO), before and after rehabilitative surgery.

Authors:  A Kłysik; M Kozakiewicz
Journal:  Eye (Lond)       Date:  2015-02-13       Impact factor: 3.775
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.